Daily FNArena News

Clinuvel Pharmaceuticals posted a strong first half result, and offers significant upside in expanding the use of its flagship drug, but investors just aren’t excited

June capped off a stellar quarter performance as the ASX200 delivered a surprisingly strong FY25 total return despite tariff, trade and geo-political headwinds, and weaker earnings

Tony Sycamore, Market Analyst, IG shares his technical views on the Nasdaq, ASX200, gold and crude oil

Industry rationalisation has made it more challenging to gain exposure to pure copper plays with recently listed Capstone offering growth for a reasonable valuation

It is not just Australia suffering a housing affordability crisis. The US is also suffering, particularly in the south, impacting Reece’s revenues and margins

Having been on the radar for a while, the recent price decline is receiving some good buying support for Evolution Mining shares, notes Fairmont Equities’ Michael Gable

New research on GQG Partners highlights higher earnings margins relative to peers due to a low-cost operating model

MFS Investment Management’s Pilar Gomez-Bravo believes heightened uncertainty and volatility are opening up opportunities in fixed income markets

Discover the key differences between the ASX100 and ASX300 indices. Learn how each index works, what companies they include, and which suits your investment goals

Wenli Zheng, Portfolio Manager at T. Rowe Price sees undervalued investment opportunities in China with significant potential for investors